

Genomic structure of the human M6P/IGF2 receptor

J. Keith Killian, Randy L. Jirtle

Departments of Radiation Oncology and Pathology, Box 3433, Duke University Medical Center, Durham, North Carolina 27710, USA

Received: 14 July 1998 / Accepted: 3 September 1998

The human mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) gene located at 6q26 (Rao et al. 1994) encodes for a multifunctional receptor that possesses distinct binding sites for phosphomannosyl glycoproteins and IGF2 (MacDonald et al. 1988; Morgan et al. 1987), retinoic acid (Kang et al. 1997), and urokinase-type plasminogen activator receptor (uPAR; Nykjaer et al. 1998). The receptor is involved in fetal development, tumor suppression, maternal regulation of intrauterine growth, and has recently been associated with the development of human cognitive ability (Chorney et al. 1998; De Souza et al. 1997; Kornfeld 1992; Wang et al. 1994). To facilitate further genetic analyses of the human M6P/IGF2R, we have determined its complete genomic organization, defined the intron-exon boundary sequences, and designed intronic oligonucleotides for PCR amplification of the 48 exons included in the 136-kb genomic sequence.

The M6P/IGF2R is a chimeric receptor possessing binding sites for four distinct classes of ligands (Kang et al. 1997; Nykjaer et al. 1998; MacDonald et al. 1988; Morgan et al. 1987). The M6P binding site enables the M6P/IGF2R to target to the lysosomes both newly synthesized lysosomal enzymes from the Golgi and phosphorylated proteolytic enzymes endocytosed from the extracellular environment (Kornfeld 1992). Furthermore, the latent complex of transforming growth factor beta (TGF β), a potent growth inhibitor, binds to the M6P/IGF2R through these M6P binding sites, thereby facilitating its activation by plasmin (Dennis and Rifkin 1991). The effectiveness of TGF β activation may be further enhanced by the direct binding of uPAR to the M6P/IGF2R (Nykjaer et al. 1998). The mammalian M6P/IGF2R also contains an independent IGF2 binding site that is absent in chickens (Zhou and Sly 1995). IGF2 binding to the M6P/IGF2R leads to lysosomal degradation rather than intracellular signaling, a process mediated by both the IGF1 and the insulin receptors (Kornfeld 1992). Therefore, loss of M6P/IGF2R function would be predicted to increase the extracellular concentration of IGF2, decrease the level of active TGF β , and increase the secretion of proteolytic enzymes. These biological effects suggest the M6P/IGF2R functions normally as a tumor suppressor.

A number of reports now strongly support this postulate for a wide variety of human tumors. Briefly, the M6P/IGF2R is mutated in 60% of dysplastic liver lesions and HCCs in patients with or without hepatitis virus (HV) infection (De Souza et al. 1995a, 1995b; Yamada et al. 1997). Its inactivation also plays a prominent role in the early stage of breast cancer development (Hankins et al. 1996), and increased expression of the wild-type receptor in breast cancer cell lines leads to apoptosis (Oates et al. 1998). Furthermore, the M6P/IGF2R gene contains a poly-G region that is a common mutational target in colon, gastric, and endometrial tumors with mismatch repair deficiencies and microsatellite instability (Souza et al. 1996). Thus, M6P/IGF2R inactivation is a frequent oncogenic event that occurs early in carcinogenesis.

A full parental complement of autosomal genes is inherited by

all offspring, but not all are biallelically expressed. The phenomenon of monoallelic expression of the same parental allele is called genomic imprinting (Surani 1998). The *M6p/Igf2r* gene is imprinted in mice (Barlow et al. 1991) and is expressed only from the maternal allele in all tissues except potentially the brain (Hu et al. 1998). In contrast, imprinting of the M6P/IGF2R gene is a polymorphic trait in humans, with most people having biallelic expression in all tissues (Xu et al. 1993). Although imprinting of the M6P/IGF2R may have provided an evolutionary advantage to the mother during the emergence of mammalian intrauterine growth (Haig and Graham 1991), monoallelic expression of this gene would also be predicted to increase cancer susceptibility. In support of this postulate, Xu et al. and associates (1997) have recently demonstrated M6P/IGF2R imprinting in 50% of Wilm's tumors.

Plomin and his colleagues have also identified the M6P/IGF2R as a putative "IQ gene" (Chorney et al. 1998). By comparing Caucasian children with an IQ of 160 or higher with those with an average IQ, they showed that the M6P/IGF2R is linked to human cognitive ability. If a polymorphism in the M6P/IGF2R coding sequence or its regulatory region is subsequently shown to functionally affect IQ, it would be the first identified gene known to contribute to intelligence. Thus, the M6P/IGF2R plays a fundamental role in biological processes ranging from embryogenesis to carcinogenesis. How the M6P/IGF2R could possess such diverse biological functions is an intriguing enigma that remains to be solved.

To facilitate future studies on the human M6P/IGF2R, we have characterized its complete genomic structure. The human cDNA sequence was divided into 48 exons based upon the mouse genomic structure (Szebenyi and Rotwein 1994), and PCR primers were designed to traverse these putative introns. All the introns except 1, 2, and 4 were amplified from human genomic DNA with either long-template PCR (Boehringer Mannheim Corp., Indianapolis, Ind.) or traditional PCR (Qiagen, Inc, Santa Clarita, Calif.). PCR products were sequenced on an ABI automated sequencer (Perkin-Elmer Corp., Foster City, Calif.). The sizes of introns 1 and 2 and their 5' and 3' boundary sequences were previously defined (Riesewijk et al. 1996; Smrzka et al. 1995); this information is available on GenBank (Accession Nos. X83699, X83700, and X83701). To sequence intron 4, human BAC clones (174E20 and 650K6) were first obtained by probing filters from Research Genetics, Inc. (Huntsville, Ala.) with an RT-PCR product spanning exons 1 to 6. A 13-kb stretch of DNA containing intron 4 was then PCR amplified from this BAC clone and the exon-intron boundaries sequenced. With the exception of intron 15, all exon-intron splice sites (93/94) conformed to the AG/GT rule (Mount 1982). Interestingly, the single intron splice site exception is also present in the mouse *M6p/Igf2r* homolog (Szebenyi and Rotwein 1994).

Intron sizes were determined by sequencing the entire intron or estimated by electrophoresis. Twenty introns were sequenced entirely (that is, introns 8, 9, 13–17, 21, 23, 24, 27, 28, 32–34, 37, 38, 42, 43, and 46), and at least 100 bp of flanking intronic sequence were determined for the remaining introns. The entire human M6P/IGF2R gene was then reconstructed with the use of the previously

Table 1. Human M6P/IGF2R intron-exon boundaries.

Exon	cDNA (nt)	Exon size (bp)	5' splice donor	Intron size (kb)	3' splice acceptor	Intron phase ^a
1	1	296	CAGgtgggtgccccecc	22.0	ttttctctccagTTA	2
2	296	140	TGGgtaagtagaactacc	17.0	ttctccaaatagGTG	1
3	437	125	CTGgtgagtcacacagg	1.5	atTTTTTaaatagGGA	0
4	562	99	GAGgtaacatgggaact	13.0	ctctccctccagGTG	0
5	661	133	TAGgtatgaatcttgg	2.0	atacatgattttcagACA	1
6	794	130	CAGgtcagtcaggcctc	2.2	atgtggctctccagGCT	2
7	924	106	GAGgtaagtactctct	2.7	cattgttctgatagGGC	0
8	1030	163	GAGgtaagcaggtgctt	0.227	tttccctgttttagGTT	1
9	1193	166	CCGgtactctcaacaact	1.315	ttcacaaaaatctagATA	2
10	1359	104	CAGgtaagtgtgcgctgg	5.5	tettgaattgtcagGTA	1
11	1463	165	CAGgtactgcctccttg	2.5	ttgttttttacagAAC	1
12	1628	141	TGGgtgagttgtccctgg	1.2	cccttctctccagATA	1
13	1769	144	CAGtataaaatTTAAAA	1.095	ttccccattgacagGTG	1
14	1913	138	CAGtctgtgtccaaagca	0.614	ttaatcttctaaGGT	1
15	2051	148	AAGgcaagtagcttctca	0.511	cgtgtgttaattagTGA	2
16	2199	178	CAGgtaggaatgtttgc	0.456	ctgccgtggattagGAA	0
17	2377	116	CAGgtgagcagagtcag	0.468	gccttgaatttagTCT	2
18	2493	169	CAGgtgaactgttttca	2.0	ctgttttctcagGGC	0
19	2662	180	CTGgtaagcactgtctgc	5.0	gatttgccattcagAAC	0
20	2842	102	CAGgtactgtgtcttcca	1.5	tttgttctctagGCT	0
21	2944	102	ATGgtaagagcagataga	0.78	ccgtctgactcgactTIT	0
22	3046	193	AAGgtgagctcagagcca	1.6	ctctgtcttaccagGTA	1
23	3239	171	CCGgtaagccgtgctggc	0.781	tttgtgtttcagACA	1
24	3410	144	AGGgtgagttctcctgg	0.105	attctgttctccagGCA	1
25	3554	176	TCCgtgtgtgttcagacc	0.8	tgatttatattacagGGC	0
26	3730	88	AAGgtaggactggcctg	1.5	tcctatgttctgaagGGG	1
27	3818	216	CAGgtaccattgtttgc	0.771	tctcctcttaccagGTC	1
28	4034	131	CGGgtgagcatgtaccga	0.271	tcttaacttttagCCA	0
29	4165	98	CAAgtaatccatggatg	3.0	ttttctctttcagAGA	2
30	4265	137	CTGgtgagagaggcctc	1.5	tgctgtgtctcagAGC	1
31	4400	191	GTGgtaaggactgttcc	1.5	tgtctctgttagAAC	0
32	4591	127	CAGgtgagagggtgtgcc	0.732	tctccaccctacagGAC	1
33	4718	120	TGGgtgagtgctgtgtgc	0.327	tcctctgtgtcagGGG	1
34	4838	257	GCCgtgagtttcagatg	0.286	tttacttaacagACC	0
35	5095	219	ATAgtaatgatgacaaat	2.0	tcgctcttttagGAT	0
36	5344	150	ATGgtaatgtggcctg	2.3	tcttctggcaacagGGA	0
37	5464	162	AAGttaatgcgtcacc	1.233	atggtttttccagGTG	0
38	5626	208	CAGgtaaatattgaaat	0.341	tcttcttctccagAAA	1
39	5834	147	ACTgtgagtaggagcgtc	3.6	ccntactccccagCAA	1
40	5981	235	CTCgtgagtgcttccca	1.0	tgtgtctttctagGTA	2
41	6216	137	TAGgtaaaggcctgtgggt	3.0	attgtgtttcagGTG	1
42	6353	115	GAGgtcagagactgggg	0.957	cttccctctctagGTT	2
43	6468	147	TAAgtaatgaaaaagttt	0.662	tttctgtctctcagGCT	2
44	6615	188	AAGgtaatccgtgcttc	6.5	cttccgtatgacagACG	1
45	6803	187	GGGgtgatgataaaatcc	5.5	gtgactgctgtcagGGT	2
46	6990	153	GAGgtaaagcgggtgcag	1.081	ccTTTTTTTaatagGGA	2
47	7143	70	AAGgtaatttctgtggc	1.8	gttgactccgtcagGTG	0
48	7213	1878				

^a Intron-exon splice junctions are categorized as phase 0, uninterrupted codon; phase 1, codon interrupted after the first nucleotide; and phase 2, codon interrupted after the second nucleotide.




Fig. 1. Genomic organization of the human M6P/IGF2R. **A)** The 48 exons of the human M6P/IGF2R are distributed over approximately 136 kb. **B)** The mRNA is subdivided into exons, and the ACAA tetranucleotide insertion (Hol et al. 1992) and the (GT)_n dinucleotide (Goto et al. 1992) polymorphic sites in the 3'-UTR (exon 48) are shown. The mRNA is also aligned with the protein sequence, which is divided into 15

structural repeats, each of approximately 150 amino acids; a 27-amino acid gap between repeats 14 and 15 (gap); a single 23-amino acid transmembrane domain (tm); and a 164-amino acid cytoplasmic tail (cyto) (Morgan et al. 1987). Repeats 3 and 9 (M) contain the M6P-binding domains, and repeat 11 (G) forms the IGF2-binding domain (Dahms et al. 1993; Schmidt et al. 1995).

Table 2. Intronic oligonucleotides for PCR amplification of the 48 human M6P/IGF2R exons.

Exon	F1 (5' to 3')	R1 (5' to 3')	Nested Primer (5' to 3') ^a
1	gctgtcacgtgacgcgggtc	accgcgagcggagcctgcctc	gcccgctgcccgtctgcF2
2	ctagtttggcgcaatttaagcaaatg	attgccaatccagtaattcagg	gataaatcagtgacattgacaggtgF2
3	ggattatgtattatagccctg	ttaagaatacatcaagtgcctctg	aatatcatcaagtcctgtgtggacR2
4	ttatttttagtgcccttactgcaattca	gataaagttccccagagtatacttc	ccagagtactctcataagcatgR2
5	ctgattgaccaagatgtatactg	gaaagcgaagatattgaagccatag	cctcaccaccaccctcagR2
6	ctaagggtacgtgtgattatcactc	gaaagtcaggtcctgctggag	aaacgccaacagcatcgaggR2
7	ggcaacatagaaattggatgtac	caaccaggtcctgctgccc	gtgcccacattagtgatcagR2
8	gtggaaaatctgcaattagctgcatg	ccttctcctaagcagcggc	caggaggcagaagaccctgR2
9	gactaagtaagactgtaattcttaatacc	cgcacagaggtgtgacgtac	aatacttattatataaaacagctcF2
10	cccaaacacatttctgtgttattc	acaagcacatgcccatgaatgc	gcaaaagaggggctgaacR2
11	gctgttcccaattttgctcagc	gaaaatgttccatgagcatgtggac	gactaagaccgcatggcaaggR2
12	gtgactcagagaatcagcattgc	ctaactcattccaactggatgc	gaaaaacatcactagatctccR2
13	gtcactcttctgtcgtgatgac	atatgaaagatcagagcctctgg	caggacctctggcagaagcR2
14	gtccctccaagtctactctagc	gtggtccaagtcacattaaagcag	cacattaaagcagaggtcctcR2
15	gtgggaacctctgggaa	cttagcatataatgccaagaatgaaac	ctaagaatgaaacagaactgagaagcR2
16	gtgactctcactgctcagc	cacagcagatgattctcagc	gtatctcaggagcgcgatgR2
17	ctcattgggaacattgctcctg	cagcaaaccttcaacctcagc	caacctcagcatctgaccagR2
18	gtaagcttactccccaaactacatag	ctcccactaagtcgaaatagg	taggaggcgaaggagacaagcR2
19	cccaacaatacgaactgactg	acataaagcagcctcagtc	aatgcagcagtgaaagctaccR2
20	agtattctttggttctatcaagtcc	gtccagcagcagctcagc	ctcagcagcagggccaggtgR2
21	gtgctgtatgtattgttctctg	gtgacttcaaatgcaactcctc	ctgtttcaaaagcaactgaaatgcR2
22	tcctgtctgtgtgagatcagag	ctacactcaggaagtgcatggc	atggccagccacagagaccR2
23	ctcactgtctgtggtggctg	gactcttgaccggcctcagtc	gaccggcctcagttcttagR2
24	gcagttctgagctcacaagg	caaatgctctaataatgaacagcgc	cagacgcaatcaagagaccaagR2
25	gagcattgactcaaggtcatcgc	gaaatgggaaatggagtcaccgc	gggacaacatctcgtctgR2
26	gattacaggtgtgagccaccgtg	catcgttcagaagctctgactctatac	aaaatgactgtgaggagagcR2
27	cgctgtgtgtgacagttgccc	ctcaagggaataatcatctcagc	gttgacagctccctcactcF2
28	gtgtcacatgtcttagcctaag	aatatgatcccagcagcctgag	gtttgacagcctagggacF2
29	caaaagtataaactaaagtgttctctcac	gcaaaatcatcacaagttagctctcc	gttttgcattctcatttataatgtF2
30	acgaccaagcctaactaactg	ctctcaccagctgctgctctg	ctctgtgatacactgcaaacR2
31	tgatgaagttctgtctagcctg	gcagaaggtgcggaacagctccc	gggagtcactaaagcactcF2
32	ccactgttagttgaaatcatgatagac	caccgtctcactcctcagc	gctgggttaacagactggacR2
33	gctcccaagctcagctc	gcaaaagagactgaggacaacc	ccctggagctactgtgtcF2
34	gaaatgatgtgctcactgctg	gcaactggagatgcaactcctc	catcagaataatggccatgagctF2
35	ggatgacatagtggtgattagc	cgcaaggtttactactaaagctctgc	gtcttgcataaataatccaccctgR2
36	ccttgggaatggtaattctg	cgcaacttctggtgtctagc	gcttggctactaaccgccagR2
37	gtcactgtctatctccctatgccc	cagcactctggcactggtacacc	gtacacctgcaccagcaagR2
38	actttgagacctgggtg	cagcttcttctgctctatgctc	gctgccactctgctgagcctF2
39	ctgaggtgattgctgctggcg	ctcagtgtaatcgaccctgac	cgaggcacagctgcccactgF2
40	gcatagacacagtgacactctgatc	gcagctcgaagttcaatcagc	gttcacatgctgaggggtgtgR2
41	cagggcagagacgtcactctg	cacttcccggctcagatgctg	gttcagatgctgctcctgaaacR2
42	gaattgacaggtgtgagccactg	ctcagatgctcactgacacag	gcaagctcccgtctgagcR2
43	gttttgcagctccctatgtctg	gcattgctggttaattgaaac	catttcacagctcagaagaaagcR2
44	ctgagggttatgtcatgaaagcc	ccttcttggaggaagttaaatgtg	gaagttaaatgtgaaactgtggR2
45	ggagctaagctcagctgctcgtg	cacttattctaaaggaaatgtg	gatgtgggttacaaggtgctagR2
46	caggtgtgctgctgagc	tagctatgagggcatgaccc	catccaccgcccccactcR2
47	ccatgccctctcactggag	cctgatgagaacgacatggacagc	ggcagggcttcaagagactcR2
48	ggctcacgtggtctctgctgtg	gctgacctcctaccctc	gcatcatcagtgtaagtcR2

^a Nested primers F2 and R2 should be paired with R1 and F1, respectively, during second-round PCR.

characterized genomic sequence for exons 1 to 3 (Riesewijk et al. 1996; Smrzka et al. 1995) and the sequence from our overlapping PCR-generated products. The complete set of intron-exon boundary sequences for the M6P/IGF2R and all of the intron and exon sizes are presented in Table 1. The codon position that is interrupted by the intron is indicated by the intron phase. The intron-exon splice junctions for the human M6P/IGF2R are identical in position to those in the mouse (Szebenyi and Rotwein 1994). The total size of the human M6P/IGF2R gene is estimated to be 136 kb (Table 1, Fig. 1). This is approximately 43 kb larger than that for the mouse gene, and introns 2 and 4 account for much of this increased size. The M6P and IGF2 receptor binding domains are also assigned to the appropriate exons (Fig. 1). The intron-exon boundary sequences were deposited with GenBank (Accession Nos. AF069333-378), and will also be available on the M6P/IGF2R Information Core (<http://www.radonc.duke.edu/~jirtle/homepage.html>).

We have also designed intronic oligonucleotides for PCR amplification of the 48 human exons, including nested primers to allow for second-round DNA amplification (Table 2). DNA amplification from formalin-fixed, paraffin-embedded tissues requires primers that minimize the size of the amplified regions while including the splice sites flanking the exons. All 48 primer

sets have been successfully employed to PCR amplify DNA isolated from either frozen tissue or formalin-fixed, paraffin-embedded samples. These nested primer sets yield a single PCR product approximately the size of the exon (Table 1) plus 80 bp. The PCR conditions used for all primer sets were 94°C × 20 s, 55°C × 30 s, and 72°C × 20 s for the 25-cycle first round and 30-cycle second round DNA amplifications.

In conclusion, we have determined the genomic structure and the intron-exon boundaries of the human M6P/IGF2R. These sequence data have been used to design PCR primers that allow for the systematic analysis of the 48 exons that encode for the human M6P/IGF2R gene. This should greatly facilitate linkage, phylogenetic, functional, and mutational analyses of the M6P/IGF2R, thereby enhancing further our understanding of this receptor's function in evolution, cancer biology, and human intelligence.

Acknowledgments. We thank Angus De Souza, Greg Falls, Douglas Marchuk, David Pulford, and Tomoya Yamada for their technical assistance; James V. Jirtle for M6P/IGF2R webpage design; Helena Abushamaa of the Duke Genetics Facility for help with BAC clone screening; and Marnee Baker and Scott Langdon for help with DNA sequencing. This study was supported by National Institutes of Health grants CA25951 and FS08823, Department of Defense Grant DAMD17-98-1-8305, Sumitomo Chemical Company, Ltd., and Zeneca Pharmaceuticals, Ltd.

References

- Barlow DP, Stöger R, Herrmann BG, Saito K, Schweifer N (1991) The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. *Nature* 349, 84–87
- Chorney MJ, Chorney K, Seese N, Owen MJ, Daniels J, et al. (1998) A quantitative trait locus associated with cognitive ability in children. *Psych Sci* 9, 159–166
- Dahms NM, Rose PA, Molkenin JD, Zhang Y, Brzycki MA (1993) The bovine mannose 6-phosphate/insulin-like growth factor II receptor, the role of arginine residues in mannose 6-phosphate binding. *J Biol Chem* 268, 5457–5463
- Dennis PA, Rifkin DB (1991) Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. *Proc Natl Acad Sci USA* 88, 580–584
- De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, et al. (1995a) Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. *Oncogene* 10, 1725–1729
- De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL (1995b) M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. *Nat Genet* 11, 447–449
- De Souza AT, Yamada T, Mills JJ, Jirtle RL (1997) Imprinted genes in liver carcinogenesis. *FASEB J* 11, 60–67
- Goto J, Figlewicz DA, Marineau C, Khodr N, Rouleau GA (1992) Dinucleotide repeat polymorphism at the IGF2R locus. *Nucleic Acids Res* 20, 923
- Haig D, Graham C (1991) Genomic imprinting and the strange case of the insulin-like growth factor II receptor. *Cell* 64, 1045–1046
- Hankins GR, De Souza AT, Bentley RC, Patel MR, Marks JR, et al. (1996) M6P/IGF2 receptor: a candidate breast tumor suppressor gene. *Oncogene* 12, 2003–2009
- Hol FA, Geurds MP, Hamel BC, Mariman EC (1992) Improving the polymorphism content of the 3' UTR of the human IGF2R gene. *Hum Mol Genet* 1, 347
- Hu JF, Oruganti H, Vu TH, Hoffman AR (1998) Tissue-specific imprinting of the mouse insulin-like growth factor II receptor gene correlates with differential allele-specific DNA methylation. *Mol Endocrinol* 12, 220–232
- Kang JX, Li Y, Leaf A (1997) Mannose-6-phosphate/insulin-like growth factor-II receptor is a receptor for retinoic acid. *Proc Natl Acad Sci USA* 94, 13671–13676
- Kornfeld S (1992) Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. *Annu Rev Biochem* 61, 307–330
- MacDonald RG, Pfeffer SR, Coussens L, Tepper MA, Brocklebank CM, et al. (1988) A single receptor binds both insulin-like growth factor II and mannose 6-phosphate. *Science* 239, 1134–1137
- Morgan DO, Edman JC, Standring DN, Fried VA, Smith MC, et al. (1987) Insulin-like growth factor II receptor as a multifunctional binding protein. *Nature* 329, 301–307
- Mount SM (1982) A catalogue of splice junction sequences. *Nucleic Acids Res* 10, 459–472
- Nykjaer A, Christensen EI, Vorum H, Hager H, Petersen CM, et al. (1998) Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. *J Cell Biol* 141, 815–828
- Oates AJ, Schumaker LM, Jenkins SB, Pearce AA, DaCosta SA, et al. (1998) The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. *Breast Cancer Res Treat* 47, 269–281
- Rao PH, Murty VVVS, Gaidano G, Hauptschein R, Dalla-Favera R, et al. (1994) Subregional mapping of 8 single copy loci to chromosome 6 by fluorescence in situ hybridization. *Cytogenet Cell Genet* 66, 272–273
- Riesewijk AM, Schepens MT, Welch TR, Van den Berg-Loonen EM, Mariman EM, et al. (1996) Maternal-specific methylation of the human *IGF2R* gene is not accompanied by allele-specific transcription. *Genomics* 31, 158–166
- Schmidt B, Kiecke-Siensen C, Waheed A, Braulke T, von Figura K (1995) Localization of the insulin-like growth factor II binding site to amino acids 1508–1566 in repeat 11 of the mannose 6-phosphate/insulin-like growth factor II receptor. *J Biol Chem* 270, 15975–14982
- Smrzka OW, Fae I, Stöger R, Kruzbauer R, Fischer GF, et al. (1995) Conservation of a maternal-specific methylation signal at the human *IGF2R* locus. *Hum Mol Genet* 4, 1945–1952
- Souza RF, Appel R, Yin J, Wang S, Smolinski KN, et al. (1996) The insulin-like growth factor II receptor gene is a target of microsatellite instability in human gastrointestinal tumours. *Nat Genet* 14, 255–257
- Surani MA (1998) Imprinting and the initiation of gene silencing in the germ line. *Cell* 93, 309–312
- Szebenyi G, Rotwein P (1994) The mouse insulin-like growth factor II/cation-independent mannose 6-phosphate (IGF-II/MPR) receptor gene: molecular cloning and genomic organization. *Genomics* 19, 120–129
- Wang ZQ, Fung MR, Barlow DP, Wagner EF (1994) Regulation of embryonic growth and lysosomal targeting by the imprinted *Igf2/Mpr* gene. *Nature* 372, 464–467
- Xu Y, Goodyer CG, Deal C, Polychronakos C (1993) Functional polymorphism in the parental imprinting of the human *IGF2R* gene. *Biochem Biophys Res Commun* 197, 747–754
- Xu YQ, Grundy P, Polychronakos C (1997) Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor. *Oncogene* 14, 1041–1046
- Yamada T, De Souza AT, Finkelstein S, Jirtle RL (1997) Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. *Proc Natl Acad Sci USA* 94, 10351–10355
- Zhou M, Sly WS (1995) Cloning and expression of the cDNA of chicken cation-independent mannose-6-phosphate receptor. *Proc Natl Acad Sci USA* 92, 9762–9766